Skip to main content
SpringerLink
Log in

Increasing number of anti-HIV drugs but no definite cure Review of anti-HIV drugs

  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

Abstract

Aim: This review surveys the different classes of drugs.

Method: We searched electronic databases and selected articles about pharmacotherapy with anti-retroviral drugs.

Results: We discuss anti-retroviral drugs: the nucleotide reverse transcriptase inhibitors (NRTIs), the non-nucleoside reverse transcriptase inhibitors (NNRTIs), and the protease inhibitors (PIs). The combination of a PI and two NRTIs is very effective and lowers the viral load to below the limit of detection. However, it is not yet possible to eliminate the virus completely. Recently, the first member of a brand new class of drugs has become available, the fusion inhibitor enfuvirtide. We also discuss the problems associated with combining anti-retroviral drugs, such as compliance, resistance and serious side effects.

Discussion. It is important to investigate new combinations with new classes of drugs, like the fusion inhibitors, for better effectiveness and fewer side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Borleff JCC, Danner SA, Lange JMA, van Everdingen JJE. CBO richtlijn antiretrovirale behandeling in Nederland. [CBO guidelines: anti-retroviral treatment in the Netherlands.] Ned Tijdschr Geneesk 2001; 136: 1585–9.

    Google Scholar 

  2. Gallant JE. Initial therapy of HIV infections. J Clin Virol 2002; 25: 317–33.

    Google Scholar 

  3. Chapman T, McGavin J, Noble S. Tenofovir disoproxil fumarate. Drugs 2003; 63: 1597–608.

    Google Scholar 

  4. Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. J Antimicrob Chem 2003; 51: 213–17.

    Google Scholar 

  5. de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beynen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42: 223–83

    Google Scholar 

  6. Hansten PD, Horn JR. Hansten and Horn's interactions analysis and management. Edmonds, Washington: H&H Publications, 1999.

    Google Scholar 

  7. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002; 35: 1219–30.

    Google Scholar 

  8. Deeks SG, Wrin T, Lieger T, Hoh R, Hayden M, Helmm NS et al. Virological and immunological consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472–80.

    Google Scholar 

  9. Aarnoutse RE, Schapiro JM, Boucher CAB, Hekster YA, Burger DM. Therapeutic drug monitoring an aid to optimizing response to antiretroviral drugs? Drugs 2003; 63: 741–53.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy and Toxicology, University Hospital of Maastricht, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands

    Leo M.L. Stolk

  2. Pharmacy Hanzeplein, Groningen, The Netherlands

    Jos F.J. Lüers

Authors
  1. Leo M.L. Stolk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jos F.J. Lüers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stolk, L.M., Lüers, J.F. Increasing number of anti-HIV drugs but no definite cure Review of anti-HIV drugs. Pharm World Sci 26, 133–136 (2004). https://doi.org/10.1023/B:PHAR.0000026815.44214.83

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:PHAR.0000026815.44214.83

Search

Navigation